FDA Finalizes ICH E6(R3) Guidance, But U.S. Timeline Still Unclear
The FDA has published the finalized ICH E6(R3) Good Clinical Practice guidance. Unlike Europe’s July 23 deadline, the U.S. implementation date is still to be announced. This creates uncertainty for sponsors and CROs operating across regions, highlighting the importance of early preparation and alignment with global standards.
Law of Attraction & Power of Imagination
In our community learning session with Giray Görbil (Clinical Marketing Coordinator at Cyntegrity), we explored the fascinating connection between the "Law of Attraction and the Power of Imagination". These two concepts, when combined, can [...]
Selling Across Cultures: Pitching to Global Clients
In today’s global market, success isn’t just about offering a great product or service it’s about connecting with people from different cultures in a meaningful way. The latest Community Learning Session with Julien Goncalves [...]
DIA 2025 Posters: Rare-Disease & CRF-RBQM Wins
Download our DIA 2025 posters and see how upfront RBQM—applied to rare-disease trials and joint CRF design—sharpens data quality, elevates patient safety, and keeps studies ICH E6(R3)-ready.